QIAGEN appoints Noel T. Doheny as Vice President Solutions for Molecular Diagnostics
Venlo, The Netherlands, January 12, 2004 - QIAGEN, N.V. (Nasdaq: QGENF; Frankfurt, Prime Standard: QIA) today announced that Noel Thomas Doheny has joined QIAGEN and starting January 5, 2004, will assume responsibility as QIAGEN's Vice President Solutions for Molecular Diagnostics. Mr. Doheny will be a member of the newly introduced Executive Committee of QIAGEN, will be based in QIAGEN's Maryland headquarters and will report to Peer M. Schatz, the Company's Chief Executive Officer.
Mr. Doheny has over 25 years experience in general management, sales and marketing, strategic planning, and business development with leading diagnostics companies including ThermoBioStar (formerly BioStar) and Bayer Diagnostics (formerly Ciba Corning Diagnostics).
Mr. Doheny joins QIAGEN from ThermoBioStar where, for the last 10 years he has held key positions. ThermoBioStar was founded in 1992 and acquired by Thermo Electron in 1998. Following the acquisition Mr. Doheny held the position of President of ThermoBioStar and most recently was Director of Strategic Planning and Business Development. In this position he was responsible for licensing, partnering, acquisition and strategic planning for the clinical diagnostics division.
In his newly created position as QIAGEN's Vice President Solutions for Molecular Diagnostics, Mr. Doheny will be responsible for QIAGEN's strategy and market development activities related to nucleic acid sample preparation for clinical diagnostics as molecular testing becomes more widely used by all clinical laboratories. Nucleic acid sample preparation for molecular diagnostic testing is seen as one of QIAGEN's most promising growth drivers and already represents approximately 20% of QIAGEN's consolidated net sales. An integral part of Mr. Doheny's role will also be to manage QIAGEN's contributions and roles in PreAnalytiX GmbH, its existing joint venture with Becton, Dickinson and Company (NYSE: BDX). PreAnalytiX TM provides integrated solutions for the collection, stabilization and processing/purification of nucleic acids for molecular diagnostic purposes.
"We are very pleased to have Noel on board with QIAGEN," said Peer M. Schatz, QIAGEN's Chief Executive Officer. "Our solutions are in the process of becoming a vital component to a newly emerging segment of the diagnostic industry: molecular diagnostics. Noel´s extensive experience in management, business development and sales and marketing in the diagnostics and also molecular diagnostics industry will fuel and further enhance QIAGEN's worldwide leading market position as a provider of innovative products and technologies for isolation, purification and handling nucleic acids in the next generation molecular diagnostics markets."
QIAGEN N.V., a Netherlands holding company with subsidiaries in Germany, the United States, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria and Canada, believes it is the world's leading provider of innovative enabling technologies and products for the separation, purification and handling of nucleic acids. The Company has developed a comprehensive portfolio of more than 320 proprietary, consumable products for nucleic acid separation, purification and handling, nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products and related services. QIAGEN's products are sold in more than 42 countries throughout the world to academic research markets and to leading pharmaceutical and biotechnology companies. In addition, the Company is positioning its products for sale into developing commercial markets, including DNA sequencing and genomics, nucleic acid-based molecular diagnostics, and genetic vaccination and gene therapy. QIAGEN employs approximately 1,600 people worldwide. Further information on QIAGEN can be found at www.qiagen.com.
Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products and markets and operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the DNA sequencing, genomics and synthetic nucleic acid-related markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including seasonal fluctuations), difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors, and the integration of acquisitions of technologies and businesses. For further information, refer to the discussion in reports that QIAGEN has filed with the U.S. Securities and Exchange Commission (SEC).
Peer M. Schatz
Dr. Solveigh Mähler